Written and maintained by CASRAI Editorial Board
Last updated
DrugBank is a comprehensive, curated bio-computational knowledgebase that unifies detailed chemical, pharmacological, and pharmaceutical data with comprehensive drug-target, mechanism of action, and drug-interaction records. Widely recognized as a foundational resource in cheminformatics and translational medicine, the platform supports drug discovery, in silico pharmacology, and adverse interaction profiling across academic institutions and the pharmaceutical industry. Within modern pharmacology research, DrugBank serves as a critical bridge linking molecular structure with clinical pharmacology and regulatory outcomes.
What it is
First launched in 2006, DrugBank combines detailed molecular-level information for small molecule and biotech therapeutics with rich sequence, genomic, and structural data for drug targets, enzymes, transporters, and carriers. Unlike generic chemical indexes, each DrugBank entry features an expert-curated “drug card” that provides textual mechanism descriptions, pharmacological properties, pharmacokinetics (absorption, distribution, metabolism, excretion), and clinical indications. The database is organized to serve both computational researchers downloading structured data and bench scientists exploring specific target mechanisms.
Who runs it and what it covers
DrugBank was created by David S. Wishart and his research group at the University of Alberta. Today, it operates as a public-private partnership (P3) between the University of Alberta and OMx Personal Health Analytics Inc. (operating commercially as DrugBank). Revenue generated from commercial software licensing and enterprise biopharma partnerships supports a dedicated curation team of pharmacologists, toxicologists, and software engineers who continuously maintain and update the open-access database alongside Canadian public research funding.
As documented in the official DrugBank 6.0 release, the platform’s scope encompasses comprehensive pharmaceutical metrics:
- Approved therapeutics: 4,563 FDA-approved drugs, spanning small molecules, biologicals, vaccines, and radiopharmaceuticals.
- Investigational compounds: 6,231 investigational and experimental agents undergoing preclinical or clinical evaluation.
- Total drug entries: 11,891 comprehensively annotated drugs, including 11,710 small molecule entities.
- Drug-drug interaction matrix: 1,413,413 cataloged drug-drug interaction (DDI) pairs, categorized with clinical descriptions, severity levels, and predicted pharmacokinetic impacts.
- Food interactions: 2,475 documented drug-food and drug-herb interactions.
- Spectral and analytical data: Experimental and predicted MS/MS spectra, 1D and 2D NMR spectra, collision cross section (CCS), retention time (RT), and retention index (RI) libraries cataloged for 9,464 small molecules.
- Metabolic pathways: Interactive graphical reaction trees depicting enzymatic breakdown pathways from parent molecules to active and inactive metabolites.
The knowledgebase follows international FAIR data principles, ensuring data assets remain Findable, Accessible, Interoperable, and Reusable across global bioinformatics networks.
How to search or use it
The DrugBank web portal provides researchers with multi-modal query tools designed for specific scientific workflows:
- Text and identifier search: Enter an International Nonproprietary Name (INN), trade brand, CAS registry number, or DrugBank ID (e.g., DB00001) into the primary search bar on the homepage, filtering by “Drugs”, “Targets”, “Pathways”, or “Indications”.
- Chemical structure querying: Open the Structure Search interface and use the integrated Marvin JS 2D chemical sketcher to draw a molecule or paste a SMILES or InChI string, executing exact match, substructure search, or Tanimoto similarity filtering.
- Molecular weight filtering: Navigate to the molecular weight filter panel to constrain search results within specified minimum and maximum atomic mass units (Da).
- Advanced query builder: Use boolean logic predicates to build targeted multi-parameter queries combining approval status (e.g., approved, investigational, withdrawn), Anatomical Therapeutic Chemical (ATC) classification, and target protein taxonomy.
- Target sequence alignment: Submit protein or nucleotide sequences to the built-in BLAST search module to identify homologous drug targets, off-target binding candidates, or peptide therapeutics.
- Interactive metabolic tree analysis: Open a designated drug card and scroll to the Metabolism section, hovering over metabolic nodes to trace parent substrates, intermediate enzymatic transformations (e.g., CYP450 isoforms), and terminal elimination products.
Strengths and limits
Evaluating the DrugBank database requires understanding its operational strengths and institutional boundaries:
- Deep target annotations: Unmatched granularity in describing pharmacodynamic mechanisms, binding affinities, and therapeutic target sites compared to uncurated chemical repositories.
- Comprehensive interaction modeling: Extensive narrative explanations of interaction mechanisms (e.g., competitive enzyme inhibition, clearance reduction) rather than raw binary flags.
- Multi-format data exports: Academic researchers can download complete XML database files (schema 5.1.x), 2D/3D Structure-Data Files (SDF), and CSV identifier cross-reference tables.
- Dual licensing structure: The public database provides open access strictly for non-commercial academic research under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial applications, proprietary screening algorithms, and clinical software integration require a commercial DrugBank API license.
- Download access governance: Bulk downloads of the complete XML dataset require account registration, institutional verification, and occasional distribution schedule updates.
Alternatives
Several major databases offer complementary capabilities for chemical biology and pharmacological investigation:
| Database | Primary Operator | Core Strength | Licensing / Access |
|---|---|---|---|
| DrugBank | University of Alberta / OMx | Curated drug-target mechanisms, DDI narratives, metabolic trees | CC BY-NC 4.0 (academic) / Commercial API |
| PubChem | National Center for Biotechnology Information (NCBI) | Massive chemical repository and high-throughput bioassay datasets | Public domain (CC0 / open access) |
| ChEMBL | European Bioinformatics Institute (EMBL-EBI) | Bioactivity data, SAR screening, and medicinal chemistry assays | Creative Commons CC BY-SA 3.0 |
| BindingDB | University of California, San Diego | Measured binding affinities (Kd, Ki, IC50) for protein-ligand pairs | Publicly accessible academic database |
| DailyMed | National Library of Medicine (NLM) / FDA | FDA-approved Structured Product Labels (package inserts) | Public domain US government database |
While DrugBank excels in structured interaction descriptions and clinical mechanism narratives, researchers requiring uncurated high-throughput screening data often cross-reference records against the PubChem bioassay repository.
Frequently asked questions
Is DrugBank free for academic research?
Yes. DrugBank provides free open access to individual web records and downloadable datasets for students, university faculty, and non-profit research staff under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Users must cite DrugBank in academic publications.
What is the difference between the DrugBank web portal and the DrugBank API?
The DrugBank web portal provides an interactive graphical interface for individual lookups, structure sketching, and manual literature review. The DrugBank API is a commercial RESTful programmatic service designed for software platforms, hospital clinical decision support systems, and automated enterprise drug discovery pipelines.
How does DrugBank curate drug-drug interactions?
DrugBank interaction entries are extracted from primary pharmacology literature, clinical trial filings, and regulatory drug labels by expert curators. Each interaction record specifies the contributing pharmacological mechanism, potential clinical manifestations, and severity classification.
Sources
- Knox C, Wilson M, Klinger CM, Wishart DS, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Research. 2024;52(D1):D1265-D1275. PMC10767804. https://academic.oup.com/nar/article/52/D1/D1265/7339744 (2026-11-07).
- DrugBank Online Official Portal. Latest Database Releases, Formats and Licensing. https://go.drugbank.com/releases/latest (2026-11-07).
- Wishart DS, Knox C, et al. DrugBank 5.0: a Major Update to the DrugBank Database for 2018. Nucleic Acids Research. 2018;46(D1):D1074-D1082. PMC5753335. https://academic.oup.com/nar/article/46/D1/D1074/4602867 (2026-11-07).
- DrugBank Online Official Portal. FAIR Guiding Principles Implementation. https://go.drugbank.com/fair (2026-11-07).
